Literature DB >> 7388443

Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.

T W Meade, G Greenberg, S G Thompson.   

Abstract

Progestogens probably have metabolic effects that may contribute to the increased risk of cardiovascular reactions associated with combined oestrogen-progestogen oral contraceptives. This possibility was investigated by a study of nearly 2000 reports to the Committee on Safety of Medicines from 1964 to 1977. The reports concerned preparations in which norethisterone acetate in doses of 1.0, 2.5, 3.0, or 4.0 mg was combined with 50 microgram of ethinyloestradiol and those in which levonorgestrel in doses of 150 or 250 microgram was combined with 30 microgram of ethinyloestradiol. Observed and expected numbers of reports were compared, using retail pharmacy purchase figures as a measure of the use of different preparations. There was a significant positive association between the dose of norethisterone acetate and deaths from stroke and ischaemic heart disease (IHD); this association was also found for all cases of these two conditions, fatal plus non-fatal. There were no associations of dose of norethisterone acetate with hypertension or venous thrombosis. The higher dose of levonorgestrel was associated with a possible excess of deaths, non-venous plus venous, and an excess of strokes. There was no association between dose of levonorgestrel and hypertension or venous thrombosis. The reports were also used to assess the relative safety of 30-microgram and 50-microgram oestrogen preparations. Those with 30 microgram of oestrogen were associated with significantly fewer reports of death and IHD (both fatal, and fatal plus non-fatal) than those with 50 microgram of oestrogen. In view of the large-scale move towards preparations with progressively lower oestrogen doses, there are no grounds for major changes in oral contraceptive practice. Within the range of preparations currently in use, however, there is a case for minimising the dose of progestogen to reduce the chances of thromboembolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7388443      PMCID: PMC1601307          DOI: 10.1136/bmj.280.6224.1157

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.

Authors:  D D Bradley; J Wingerd; D B Petitti; R M Krauss; S Ramcharan
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

2.  Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism.

Authors:  V Wynn; P W Adams; I Godsland; J Melrose; R Niththyananthan; N W Oakley; M Seed
Journal:  Lancet       Date:  1979-05-19       Impact factor: 79.321

3.  Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen.

Authors:  T W Meade; A P Haines; W R North; R Chakrabarti; D J Howarth; Y Stirling
Journal:  Lancet       Date:  1977-11-05       Impact factor: 79.321

4.  Low conversion of 19-nortestosterone to urinary oestrogens.

Authors:  J D Townsley; H J Brodie
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321

5.  Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.

Authors:  W H Inman; M P Vessey; B Westerholm; A Engelund
Journal:  Br Med J       Date:  1970-04-25
  5 in total
  19 in total

Review 1.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Trends in the content and use of oral contraceptives in the United States, 1964-88.

Authors:  B B Gerstman; T P Gross; D L Kennedy; R C Bennett; D K Tomita; B V Stadel
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

3.  Oral contraceptive estrogen content and adverse effects.

Authors:  M Russell; S Ramcharan
Journal:  Can Fam Physician       Date:  1987-02       Impact factor: 3.275

4.  The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women.

Authors:  S G Thompson; T W Meade; G Greenberg
Journal:  J Epidemiol Community Health       Date:  1989-06       Impact factor: 3.710

5.  Effect of different oestrogen doses on final height reduction in girls with constitutional tall stature.

Authors:  A Grüters; P Heidemann; H Schlüter; P Stubbe; B Weber; H Helge
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

6.  Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.

Authors:  T W Meade
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

7.  Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.

Authors:  M Cortellaro; T Nencioni; C Boschetti; S Ortolani; F Buzzi; B Francucci; M P Caraceni; P Abelli; F Polvani; C Zanussi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Prevention of coronary heart disease.

Authors:  C R Kay
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

9.  Latest views on pill prescribing.

Authors:  C R Kay
Journal:  J R Coll Gen Pract       Date:  1984-11

Review 10.  Hepatobiliary complications of oral contraceptives.

Authors:  M C Lindberg
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.